Should clearance be normalised to body surface or to lean body mass?
about
Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trialPriority Setting and Influential Factors on Acceptance of Pharmaceutical Recommendations in Collaborative Medication Reviews in an Ambulatory Care Setting - Analysis of a Cluster Randomized Controlled Trial (WestGem-Study)Comparison of high vs. normal/low protein diets on renal function in subjects without chronic kidney disease: a systematic review and meta-analysisFactors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administrationNew concepts in antimalarial use and mode of action in dermatology.Moxifloxacin dosing in post-bariatric surgery patients.Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosisPopulation pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studiesPopulation pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategyGender differences in pharmacokinetics of maintenance dosed buprenorphine.Pharmacokinetics of ceftazidime in male and female volunteersA comparative randomized study of paravertebral block versus wound infiltration of bupivacaine in modified radical mastectomy.Population pharmacokinetics of gentamicin in patients with cancer.Relationships among liver and kidney volumes, lean body mass and drug clearance.Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studiesPharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.Serum C-reactive protein and leptin for assessment of nutritional status in patients on maintenance hemodialysis.Decreased maximal aerobic capacity in pediatric chronic kidney disease.Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.Cardiorespiratory fitness and sports activities in children and adolescents with solitary functioning kidney.Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CTCreatinine corrections for estimating children's and adult's pesticide intake doses in equilibrium with urinary pesticide and creatinine concentrations.Ghrelin and its Association with Nutritional and Inflammatory Status of Patients on Maintenance Hemodialysis in a South Indian Tertiary Care Hospital.Normal isometric strength of rotatorcuff muscles in adults.The Effect of Sex and Anthropometry on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Complex Coronary Lesions.Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.Accuracy of GFR estimating equations in a large Swedish cohort: implications for radiologists in daily routine and research.Normalization of glomerular filtration rate in obese children.Creatinine clearance, different methods of determination.Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients.Maturation and growth of renal function: dosing renally cleared drugs in children.Optimized dose regimen for whole-body FDG-PET imaging.Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Creatinine clearance, different methods of determination: A reply.
P2860
Q28359772-52C5A354-7A78-40B7-813E-FE3E3C7AF394Q28552615-F98FEAE5-744F-44D0-89D2-529234A1A883Q33650671-9FCD20B6-6B12-4E07-B646-91E843A7F6D3Q33939772-5A5AEA0C-C0B9-41AA-8CCF-714228F29CCAQ33979054-005571A9-9F2D-40AE-B14B-452496342F4FQ34007922-B8F1B2BB-4548-4690-8694-06F6BCCA946BQ34209532-9267D727-1F16-425F-9C16-1C47021F75E3Q34347531-9BBEFF7D-9D18-4561-8D1F-8D54F331A90EQ34824085-75A39BE4-DE40-4E8E-AF50-245C80E70277Q35043725-EA14AAC1-94BC-4BFD-B7B2-9B8A5188956BQ35120597-A42587DB-18D1-4D82-9A81-4CF7EC339A08Q35122861-9138FF8D-0CAA-4C9E-8EDE-3826FC2A8B41Q35124143-21EC4D7F-EDCE-48DF-90DD-44B84C115229Q35184385-D1285B91-6CBC-4019-875A-810D8D689D8AQ35745171-A9D5D62A-67F6-4B09-A35D-3BBFE89F3426Q35746326-B73C4C64-F405-4D55-876A-01391CBDEECEQ35802610-CEBB9377-B7C7-4254-9F5D-C2DA3A867452Q35802646-23F01A8C-22B1-43A6-ADB4-2A646D59F0A7Q36054988-584ACC22-A093-42BC-9A05-981A18B6564AQ36094883-E19F88E3-C340-4823-A21B-21B0F47EEE78Q36236032-95D005C5-8FA4-4251-9F55-C35188C1C80EQ36612801-5C724F1E-7861-4C11-97D0-063C4267880EQ36667255-0CF06CF9-5A66-439B-A89F-04ED8A8EFDA6Q36753385-B7937309-5752-4284-AACA-2E38F834F490Q36842310-FEEF8295-3A2E-4BFF-A80A-7705107DFF60Q36922309-87028B19-CEF9-46D5-B4E3-E718E9E65911Q36945544-6AC884C1-A58B-4B5C-ABE0-FA0F112C9ED3Q37045876-0DC72D7E-1D42-40BE-AB38-38E92489A8E5Q37220024-574B4A8C-D72A-4D0C-95B8-22234EB8DD46Q37622133-02DA04E2-F1C5-424C-ACB1-E8195F34A208Q39656587-C0FDD769-7C84-4583-9600-43878F4C0598Q39776605-6308325A-E20C-4EC5-95FE-F9CB3E01F31EQ40836399-3B3615F5-52FE-4176-9021-D8F1295CB976Q41875633-7E56CC2E-8338-4E21-BEDE-FD01A67732F7Q41991414-DB5A3F27-32D7-4B8B-92E4-FA6CF991D618Q42030741-169BDEE1-4B9F-428B-B2E8-0AC2A5D71CAAQ42565767-9E3FF11D-1984-4988-B7D1-3ECE32B93F0EQ45875808-505BEEDD-11FE-4FC5-A491-E08460E67DE6Q46433362-164F6EE5-517A-4F9D-9BB5-CAA51F810E39Q46515408-FE4CA970-143C-48CD-B2A8-8095DF3411F3
P2860
Should clearance be normalised to body surface or to lean body mass?
description
1981 nî lūn-bûn
@nan
1981 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Should clearance be normalised to body surface or to lean body mass?
@ast
Should clearance be normalised to body surface or to lean body mass?
@en
Should clearance be normalised to body surface or to lean body mass?
@nl
type
label
Should clearance be normalised to body surface or to lean body mass?
@ast
Should clearance be normalised to body surface or to lean body mass?
@en
Should clearance be normalised to body surface or to lean body mass?
@nl
prefLabel
Should clearance be normalised to body surface or to lean body mass?
@ast
Should clearance be normalised to body surface or to lean body mass?
@en
Should clearance be normalised to body surface or to lean body mass?
@nl
P2093
P2860
P1476
Should clearance be normalised to body surface or to lean body mass?
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1981.TB01163.X
P407
P577
1981-05-01T00:00:00Z